{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:23:16Z","timestamp":1785367396742,"version":"3.55.0"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.msard.2025.106541","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:30:06Z","timestamp":1747942206000},"page":"106541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Approach to JCV testing with natalizumab biosimilar: a UK consensus statement"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-585X","authenticated-orcid":false,"given":"Ruth","family":"Dobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarunya","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Varley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A","family":"Muraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Petheram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqar","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Tallantyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Anand","family":"Trip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106541_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106421","article-title":"Critical issues in recommending extended interval dosing","author":"Cutter","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106541_bib0006","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2023.2221027","article-title":"Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world","volume":"22","author":"Dsilva","year":"2023","journal-title":"Expert Opin. Drug. Saf."},{"key":"10.1016\/j.msard.2025.106541_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421998915","article-title":"High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients","volume":"14","author":"Dwyer","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106541_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104251","article-title":"Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis","volume":"68","author":"Gaughan","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106541_bib0008","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaneurol.2025.0337","article-title":"Accuracy of new John Cunningham virus antibody assay in natalizumab-treated patients with multiple sclerosis","volume":"82","author":"Gelissen","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2025.106541_bib0002","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","volume":"1","author":"Gonzalez-Lorenzo","year":"2024","journal-title":"Cochrane Database. Syst. Rev."},{"key":"10.1016\/j.msard.2025.106541_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174005","article-title":"Stability and predictive value of anti-JCV antibody index in multiple sclerosis: a 6-year longitudinal study","volume":"12","author":"Hegen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2025.106541_bib0010","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3389\/fimmu.2018.02435","article-title":"Impact of disease-modifying treatments on the longitudinal evolution of anti-JCV antibody index in multiple sclerosis","volume":"9","author":"Hegen","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106541_bib0007","article-title":"Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: a call for standardization and transparency in clinical practice","author":"Inojosa","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106541_bib0001","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/brain\/awaa231","article-title":"Delay from treatment start to full effect of immunotherapies for multiple sclerosis","volume":"143","author":"Roos","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106541_bib0003","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40261-024-01360-4","article-title":"PB006: a Natalizumab Biosimilar","volume":"44","author":"Shirley","year":"2024","journal-title":"Clin. Drug Investig"},{"key":"10.1016\/j.msard.2025.106541_bib0005","unstructured":"Tyruko 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc). https:\/\/www.medicines.org.uk\/emc\/product\/15571\/smpc#gref. Accessed May 2025."},{"key":"10.1016\/j.msard.2025.106541_bib0004","unstructured":"TYSABRI 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc). https:\/\/www.medicines.org.uk\/emc\/product\/222\/smpc#gref. Accessed May 2025."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:11:59Z","timestamp":1754003519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825002834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":13,"alternative-id":["S2211034825002834"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106541","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approach to JCV testing with natalizumab biosimilar: a UK consensus statement","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106541"}}